Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07304674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Association Between Primary Aldosteronism and Cognitive Dysfunction

Study acronym: PACD
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2025 to Dec 31, 2025
    • Site details revised at 2 of 2 sites
    v3
  2. Primary endpoints revised (2)
    • Secondary endpoints revised (25)
    • Study description expanded, about 2 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are: 1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.
Trial Details
NCT Number NCT07304674
Lead Sponsor Xinjiang Medical University
Conditions
(from sponsor)		 Primary Aldosteronism, Cognitive Dysfunction, Mild Cognitive Impairment (MCI), Dementia
Related terms Cognitive Dysfunction, Dementia, Hyperaldosteronism
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov